STOCK TITAN

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

Rhea-AI Impact
(High)
Rhea-AI Sentiment
(Neutral)
Tags
Jaguar Health (NASDAQ:JAGX) announced that its founder, president and CEO Lisa Conte will deliver a virtual presentation at the Emerging Growth Conference on June 18, 2025, from 9:40 - 10:10 AM Eastern Time. The presentation will be available online, with a replay accessible through EmergingGrowth.com and the Emerging Growth YouTube Channel. This conference presentation aims to provide updates on near-term catalysts for the company.
Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction

-6.23%
1 alert
-6.23% News Effect

On the day this news was published, JAGX declined 6.23%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Click here to register

SAN FRANCISCO, CA / ACCESS Newswire / June 17, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Wednesday, June 18, 2025 at the Emerging Growth Conference.

Participation Instructions for Jaguar's Virtual Presentation at the Emerging Growth Conference

When: Wednesday, June 18, 2025 from 9:40 - 10:10 AM Eastern Time

Where: Online (Click Here)

Registration link for conference: Click Here

Replay: An archived webcast of the presentation will be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will present at the June 2025 Emerging Growth Conference. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.



View the original press release on ACCESS Newswire

FAQ

When is Jaguar Health (JAGX) presenting at the Emerging Growth Conference?

Jaguar Health is presenting on Wednesday, June 18, 2025, from 9:40 - 10:10 AM Eastern Time.

Who will be presenting for Jaguar Health (JAGX) at the Emerging Growth Conference?

Lisa Conte, Jaguar Health's founder, president and CEO, will be delivering the virtual presentation.

How can investors watch Jaguar Health's (JAGX) Emerging Growth Conference presentation?

Investors can watch the presentation online through the conference platform, with replays available on EmergingGrowth.com and the Emerging Growth YouTube Channel.

What topics will be covered in Jaguar Health's (JAGX) presentation?

The presentation will provide updates on near-term catalysts for the company.
Jaguar Health Inc

NASDAQ:JAGX

JAGX Rankings

JAGX Latest News

JAGX Latest SEC Filings

JAGX Stock Data

3.05M
2.19M
34.76%
0.63%
3.04%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO